Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017
14 févr. 2017 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth-quarter 2016 financial results on Tuesday, February 28, 2017, after the close of the U.S....
Tesaro Announces Participation in Three Investor Conferences
21 nov. 2016 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor...
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer
01 nov. 2016 16h30 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug...
TESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMA
27 oct. 2016 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
08 oct. 2016 02h15 HE
|
TESARO, Inc.
Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...
TESARO Announces First-Quarter 2016 Operating Results
05 mai 2016 16h05 HE
|
TESARO, Inc.
U.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant submittedNiraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a...
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
04 avr. 2016 08h00 HE
|
TESARO, Inc.
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P....
TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
14 mars 2016 08h05 HE
|
TESARO, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
TESARO Outlines Business Priorities and Strategic Outlook for 2016
11 janv. 2016 08h15 HE
|
TESARO, Inc.
U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned...